Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.
Hyeong Seok KimMirang LeeYoungmin HanJae-Seung KangYoon Hyung KangHee Ju SohnWooil KwonDong Ho LeeJin-Young JangPublished in: Journal of hepato-biliary-pancreatic sciences (2023)
NAT showed better survival than upfront surgery in resectable pancreatic cancer. In patients with PV/SMV contact or CA19-9>150 U/mL, NAT showed a survival difference compared to upfront surgery; therefore, NAT could be considered in these patients.
Keyphrases
- minimally invasive
- locally advanced
- coronary artery bypass
- end stage renal disease
- newly diagnosed
- rectal cancer
- ejection fraction
- lymph node
- squamous cell carcinoma
- liver metastases
- prognostic factors
- surgical site infection
- free survival
- radiation therapy
- atrial fibrillation
- patient reported
- smoking cessation
- combination therapy